Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.7)
Main Sectors:
58 Stocks
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ITCI Intra-Cellular Thera... | Reiterates: Neutral | 132 132 | n/a | n/a | 22 | Apr 2, 2025 | |
CMPS Compass Pathways | Reiterates: Overweight | n/a | n/a | n/a | 6 | Mar 28, 2025 | |
ACAD ACADIA Pharmaceutica... | Reiterates: Overweight | 28 28 | 21.8 | 28.44% | 21 | Feb 27, 2025 | |
JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | 140 150 | 139.48 | 7.54% | 6 | Feb 26, 2025 | |
AXSM Axsome Therapeutics | Reiterates: Overweight | 153 153 | 120.3 | 27.18% | 22 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 14 | 13.1 | 6.87% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 17 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 7 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 4 | n/a | n/a | 9 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 51 58 | 27.28 | 112.61% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 43 | 31.06 | 38.44% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 155 155 | 137.03 | 13.11% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 35 35 | 15.42 | 126.98% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 13 | 5.43 | 139.41% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 34 34 | 20.84 | 63.15% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 330 330 | n/a | n/a | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 38 45 | n/a | n/a | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 52 50 | 40.86 | 22.37% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | 5.9 | -15.25% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 7 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 | n/a | n/a | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 | 1.04 | 284.62% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 58 | 39.61 | 46.43% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 10 | n/a | n/a | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 1100 | 1.95 | 56310.26% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 80 | 10.51 | 661.18% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 172 | n/a | n/a | 12 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 | 1.07 | 180.37% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 11 | 9.96 | 10.44% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 9 12 | 9.88 | 21.46% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 146 168 | 9.46 | 1675.9% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 5 | n/a | n/a | 4 | Apr 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.44 | 719.67% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 200 | 24.1 | 729.88% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 52 | n/a | n/a | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 8 4 | 1.84 | 117.39% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | 3.63 | 561.16% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 372 144 | 2.43 | 5825.93% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 26 | n/a | n/a | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 24 35 | n/a | n/a | 3 | Sep 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 3 4 | 1.35 | 196.3% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 1224 1440 | n/a | n/a | 4 | May 19, 2020 |